VAST
A wider horizon, held close. VAST carries the grounded, patient character of mescaline — spacious in feeling, embodied in presence, and built for the long view.
formula.
VAST is the mescaline line — grounded, expansive and unhurried. Its language draws from the qualities historically associated with the molecule while keeping character, reported experience and established evidence clearly separate.
WIDER PERSPECTIVE
More room around the immediate problem. VAST is framed for reflection, context and the longer horizon — an intention, not a guaranteed cognitive effect.
EMBODIED PRESENCE
Earthbound, sensory and body-aware is the character most often associated with mescaline. Response is individual, and very-low-dose use has not been clinically characterized.
PATIENT ATTENTION
A steadier pace for work that benefits from patience rather than urgency. Controlled studies establish mescaline’s pharmacology at much higher doses, not a productivity promise here.
A different format.
VAST now shares the same compact 4mL presentation as LUCID and GLOW. Its 50mg/mL specification resolves to 1mg per nominal drop and 200mg nominal total.
THE FORMULATION LOGIC
At 0.02mL per nominal drop, 50mg/mL resolves to 1mg. That is transparent label arithmetic, not a clinically established dose.
THE LONGER HORIZON
Mescaline produced a longer average acute experience than LSD or psilocybin in a controlled comparison at studied doses. Low-dose timing is not established.
NO UNIVERSAL SCHEDULE
There is no validated microdosing schedule for mescaline and no evidence-based frequency recommendation for very-low-dose VAST use.
Label arithmetic: 4mL × 50mg/mL = 200mg nominal total. At 0.02mL per drop, 50mg/mL × 0.02mL = 1mg per nominal drop, yielding approximately 200 nominal drops. Finished batches still require fill-volume, homogeneity and delivered-drop verification.
The shared 4mL vessel brings VAST back into the same measured physical system as LUCID and GLOW. Every element exists to keep the specification easier to verify, read and handle.
the same as certainty.
Mescaline is psychoactive. Human trials show dose-dependent subjective and cardiovascular effects at studied doses, but those controlled findings do not establish the safety or benefits of very-low-dose VAST use.
BODY & IMPAIRMENT
Studied doses increased blood pressure, heart rate and body temperature, with nausea and headache reported. Do not drive or undertake hazardous activity.
HEALTH & MEDICATIONS
Cardiovascular conditions, medication interactions and personal or family psychiatric history require qualified individual review.
LEGAL STATUS
Mescaline and its salts are controlled under Schedule III in Canada, subject to a specific peyote exception. Law varies by jurisdiction.
VAST is built around a real molecule and an honest boundary. The science page covers mescaline’s 5-HT2A pharmacology, its unusually long clinical arc, the exact label math, the primary human studies and what remains unknown at very low doses.
PHARMACOLOGY
Slow absorption, 5-HT2A-mediated acute effects and a clinical time course that differs from LUCID and GLOW.
DOSE & EVIDENCE GAP
Controlled human studies used 100–800mg. The VAST specification is formulation logic, not a clinically validated microdose.
PRIMARY RESEARCH
The controlled dose, safety, pharmacokinetic and comparative studies behind every scientific statement.
Three distinct profiles.